ArticleProceedings of the National Academy of Sciences of the United States of America2008
Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 67 citations in OpenAlex.
- Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation.Haematologica · 2014Trial
- Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma.Nature communications · 2025Article
- MutatedFrontiers in immunology · 2025Article
- The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.Frontiers in immunology · 2024Review
- Genome-wide landscape of runs of homozygosity and differentiation across Egyptian goat breeds.BMC genomics · 2023Article
- Influence of DM-sensitivity on immunogenicity of MHC class II restricted antigens.Journal for immunotherapy of cancer · 2021Article
- Discovery and Differential Processing of HLA Class II-Restricted Minor Histocompatibility Antigen LB-PIP4K2A-1S and Its Allelic Variant by Asparagine Endopeptidase.Frontiers in immunology · 2020Article
- HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.Frontiers in immunology · 2020Article
- Chaperone protein HSC70 regulates intercellular transfer of Y chromosome antigen DBY.The Journal of clinical investigation · 2019Article
- Natural T-cell ligands that are created by genetic variants can be transferred between cells by extracellular vesicles.European journal of immunology · 2018Article
- CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.Frontiers in immunology · 2018Article
- Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis.Nature reviews. Rheumatology · 2017Review
- Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.Bone marrow transplantation · 2016Review
- Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets.Frontiers in immunology · 2016Review
- Allo-reactive T cells for the treatment of hematological malignancies.Molecular oncology · 2015Review
- Piperine inhibits type II phosphatidylinositol 4-kinases: a key component in phosphoinositides turnover.Molecular and cellular biochemistry · 2014Article
- Allogeneic T cells: maestro in the co-ordination of the immune response after hematopoietic stem cell transplantation.Haematologica · 2014Article
- Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.Haematologica · 2012Article
- Article
- Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.Immunology and cell biology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with hematological malignancies can be successfully treated with HLA-matched T cell-depleted allogeneic stem cell transplantation (alloSCT) and subsequent donor lymphocyte infusions (DLIs). The efficacy of DLI is mediated by donor T cells recognizing minor histocompatibility antigens (mHags) on malignant recipient cells. Because HLA class II molecules are predominantly expressed on hematopoietic cells, mHag-specific CD4(+) T cells may selectively mediate graft versus leukemia (GvL) reactivity without graft versus host disease (GvHD). In this study, we used a recombinant bacteria cDNA library for the identification of the first autosomal HLA class II (HLA-DQB1*0603)-restricted mHag LB-PI4K2B-1S encoded by the broadly expressed phosphatidylinositol 4-kinase type II beta gene. A polyclonal CD4(+) T cell response against LB-PI4K2B-1S was demonstrated in a patient with relapsed chronic myeloid leukemia (CML) who responded to DLI after HLA-matched alloSCT. LB-PI4K2B-1S-specific CD4(+) T cells recognized and lysed the CD34(+) CML cells of the patient and other leukemic cells as well as high HLA-DQ-expressing normal hematopoietic cells. HLA-DQ expression on normal cells of nonhematopoietic origin was moderately up-regulated by IFN-gamma and not sufficient for T cell recognition. We hypothesize that LB-PI4K2B-1S-specific CD4(+) T cells contributed to the antitumor response by both directly eliminating malignant cells as effector cells and stimulating CD8(+) T cell immunity as helper cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.